Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 AxisJunaid Abdulghani, Wafik S. El‐Deiry|PLoS ONE|2013Cited by 46